Yanyan Chen, Yanchen Liu, Zhicheng Gong, Zhaohui Huang. Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101343
Citation:
|
Yanyan Chen, Yanchen Liu, Zhicheng Gong, Zhaohui Huang. Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101343
|
Yanyan Chen, Yanchen Liu, Zhicheng Gong, Zhaohui Huang. Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101343
Citation:
|
Yanyan Chen, Yanchen Liu, Zhicheng Gong, Zhaohui Huang. Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101343
|
Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer
-
a. Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214062, China;
-
b. Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, 214122, China
- Received Date:
Dec. 01, 2024
- Accepted Date:
May 08, 2025
- Rev Recd Date:
Apr. 19, 2025
- Available Online:
May 14, 2025